{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=95&state=Ohio",
    "query": {
      "state": "Ohio",
      "city": "Cincinnati",
      "page": 95
    },
    "page_size": 10
  },
  "pagination": {
    "page": 95,
    "page_size": 10,
    "total_count": 10572,
    "total_pages": 1058,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=96&state=Ohio&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=94&state=Ohio&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T06:08:58.607Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04468061",
      "title": "Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Triple Negative Breast Cancer",
        "PD-L1 Negative"
      ],
      "interventions": [
        {
          "name": "Sacituzumab Govitecan",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2020-07-20",
      "completion_date": "2029-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-11-19T06:08:58.607Z",
      "location_count": 15,
      "location_summary": "Stamford, Connecticut • Miami, Florida • Plantation, Florida + 12 more",
      "locations": [
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Brewer",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04468061"
    },
    {
      "nct_id": "NCT03289273",
      "title": "Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Liver Neoplasms"
      ],
      "interventions": [
        {
          "name": "Regorafenib (Stivarga, BAY73-4506)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1010,
      "start_date": "2017-09-13",
      "completion_date": "2022-06-21",
      "has_results": false,
      "last_update_posted_date": "2023-06-13",
      "last_synced_at": "2026-11-19T06:08:58.607Z",
      "location_count": 17,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Gainesville, Florida + 13 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03289273"
    },
    {
      "nct_id": "NCT00240253",
      "title": "A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "pramlintide acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 200,
      "start_date": "2005-10",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2015-03-31",
      "last_synced_at": "2026-11-19T06:08:58.607Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Concord, California • La Jolla, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Gatos",
          "state": "California"
        },
        {
          "city": "Salinas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00240253"
    },
    {
      "nct_id": "NCT01090739",
      "title": "Clinical Study to Investigate the Effectiveness of the TOPAS System to Treat Fecal Incontinence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fecal Incontinence"
      ],
      "interventions": [
        {
          "name": "TOPAS Treatment for Fecal Incontinence",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "ASTORA Women's Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 207,
      "start_date": "2010-04",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2016-08-26",
      "last_synced_at": "2026-11-19T06:08:58.607Z",
      "location_count": 14,
      "location_summary": "San Francisco, California • Tampa, Florida • Weston, Florida + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Toccoa",
          "state": "Georgia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01090739"
    },
    {
      "nct_id": "NCT06324201",
      "title": "The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Paroxysmal Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Ablation Procedure",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Heart Rhythm Clinical and Research Solutions, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2024-02-27",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2025-10-31",
      "last_synced_at": "2026-11-19T06:08:58.607Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Ventura, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Naples",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06324201"
    },
    {
      "nct_id": "NCT01492101",
      "title": "The BEACON Study (Breast Cancer Outcomes With NKTR-102)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Recurrent Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "NKTR-102",
          "type": "DRUG"
        },
        {
          "name": "Treatment of Physician's Choice (TPC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 852,
      "start_date": "2011-12",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2021-06-01",
      "last_synced_at": "2026-11-19T06:08:58.607Z",
      "location_count": 88,
      "location_summary": "Flagstaff, Arizona • Burbank, California • Los Angeles, California + 74 more",
      "locations": [
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01492101"
    },
    {
      "nct_id": "NCT07136012",
      "title": "OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Olpasiran",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "105 Years",
        "sex": "ALL",
        "summary": "50 Years to 105 Years"
      },
      "enrollment_count": 11000,
      "start_date": "2025-08-22",
      "completion_date": "2031-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-19T06:08:58.607Z",
      "location_count": 206,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 168 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07136012"
    },
    {
      "nct_id": "NCT06868212",
      "title": "A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria (CSU)"
      ],
      "interventions": [
        {
          "name": "Remibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Remibrutinib matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo solution for injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 409,
      "start_date": "2025-07-11",
      "completion_date": "2027-05-17",
      "has_results": false,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-19T06:08:58.607Z",
      "location_count": 121,
      "location_summary": "Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Payson",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06868212"
    },
    {
      "nct_id": "NCT04684381",
      "title": "Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "L-glutamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emmaus Medical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2021-01-04",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2022-08-02",
      "last_synced_at": "2026-11-19T06:08:58.607Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684381"
    },
    {
      "nct_id": "NCT06034392",
      "title": "CHAMP App Cardiac Study and Repository",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heart Defects, Congenital",
        "Pediatrics"
      ],
      "interventions": [
        {
          "name": "CHAMP App",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Lori Erickson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2023-08-25",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-19T06:08:58.607Z",
      "location_count": 9,
      "location_summary": "Washington D.C., District of Columbia • Miami, Florida • New Orleans, Louisiana + 6 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06034392"
    }
  ]
}